BRPI1007237A2 - composição farmacêutica compreendendo aleglitazar - Google Patents

composição farmacêutica compreendendo aleglitazar

Info

Publication number: BRPI1007237A2
Authority: BR; Brazil
Prior art keywords: aleglitazar; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2009-01-23

Application number

BRPI1007237A

Other languages

English (en)

Inventor

Alexander Glomme

Paul Wojtera

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-23

Filing date

2010-01-13

Publication date

2016-02-16

2010-01-13 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2016-02-16 Publication of BRPI1007237A2 publication Critical patent/BRPI1007237A2/pt

2019-05-28 Publication of BRPI1007237B1 publication Critical patent/BRPI1007237B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

BRPI1007237-3A 2009-01-23 2010-01-13 Composição farmacêutica compreendendo aleglitazar BRPI1007237B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09151254.1		2009-01-23
EP09151254		2009-01-23
PCT/EP2010/050343 WO2010084066A1 (en)	2009-01-23	2010-01-13	Pharmaceutical composition comprising aleglitazar

Publications (2)

Publication Number	Publication Date
BRPI1007237A2 true BRPI1007237A2 (pt)	2016-02-16
BRPI1007237B1 BRPI1007237B1 (pt)	2019-05-28

Family

ID=42112184

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007237-3A BRPI1007237B1 (pt)	2009-01-23	2010-01-13	Composição farmacêutica compreendendo aleglitazar

Country Status (25)

Country	Link
US (2)	US20100190835A1 (pt)
EP (1)	EP2389166B1 (pt)
JP (1)	JP5619027B2 (pt)
KR (2)	KR20140002812A (pt)
CN (1)	CN102292074B (pt)
AR (1)	AR075041A1 (pt)
AU (1)	AU2010206249B2 (pt)
BR (1)	BRPI1007237B1 (pt)
CA (1)	CA2748896C (pt)
CL (1)	CL2011001777A1 (pt)
CY (1)	CY1113641T1 (pt)
DK (1)	DK2389166T3 (pt)
ES (1)	ES2397558T3 (pt)
HR (1)	HRP20130108T1 (pt)
IL (1)	IL213671A (pt)
MX (1)	MX2011007381A (pt)
PE (2)	PE20120421A1 (pt)
PL (1)	PL2389166T3 (pt)
PT (1)	PT2389166E (pt)
RU (1)	RU2537224C2 (pt)
SG (1)	SG173058A1 (pt)
SI (1)	SI2389166T1 (pt)
TW (1)	TWI406861B (pt)
WO (1)	WO2010084066A1 (pt)
ZA (1)	ZA201104670B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013181384A1 (en)	2012-05-31	2013-12-05	Ratiopharm Gmbh	Solid state forms of aleglitazar sodium
WO2014016369A1 (en)	2012-07-27	2014-01-30	Ratiopharm Gmbh	Pharmaceutical formulation comprising aleglitazar and complexing agent
WO2014016371A1 (en)	2012-07-27	2014-01-30	Ratiopharm Gmbh	Micronized aleglitazar
WO2014016370A1 (en) *	2012-07-27	2014-01-30	Ratiopharm Gmbh	Amorphous aleglitazar
MX2015002095A (es) *	2012-09-12	2015-05-11	Hoffmann La Roche	Formas solidas de acido (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxaz ol-4-il)-etoxi]benzo[b]tiofen-7-il}propionico y de sales del mismo.
CN116172869A (zh) *	2016-08-10	2023-05-30	豪夫迈·罗氏有限公司	包含Akt蛋白激酶抑制剂的药物组合物
CN114404375B (zh) *	2022-01-21	2023-06-27	武汉九珑人福药业有限责任公司	一种叶酸固体制剂及其原料组合物、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2772615B1 (fr) *	1997-12-23	2002-06-14	Lipha	Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
MXPA03010435A (es) *	2001-05-15	2004-03-09	Hoffmann La Roche	Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
GB0303600D0 (en) *	2003-02-17	2003-03-19	Glaxo Group Ltd	Novel therapeutic method and compositions
US7262303B2 (en) *	2003-09-29	2007-08-28	Hoffman-La Roche Inc.	Process for the production of chiral propionic acid derivatives
US20060051413A1 (en) *	2004-09-08	2006-03-09	Chow Sing S M	Method of enhancing absorptions of transmucosal administration formulations
KR20070094666A (ko) *	2005-02-25	2007-09-20	에프. 호프만-라 로슈 아게	약제 물질 분산성이 향상된 정제
US20060270722A1 (en) *	2005-05-31	2006-11-30	Thornberry Nancy A	Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
FR2894477A1 (fr) *	2005-12-13	2007-06-15	Galderma Res & Dev	Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US20100210692A1 (en) *	2007-03-28	2010-08-19	Farmer Stephen R	Methods of treatment using sirt modulators and compositions containing sirt1 modulators

2010
- 2010-01-13 KR KR1020137032602A patent/KR20140002812A/ko not_active Ceased
- 2010-01-13 AU AU2010206249A patent/AU2010206249B2/en not_active Ceased
- 2010-01-13 EP EP10701340A patent/EP2389166B1/en not_active Not-in-force
- 2010-01-13 CN CN2010800050015A patent/CN102292074B/zh not_active Expired - Fee Related
- 2010-01-13 PE PE2011001309A patent/PE20120421A1/es not_active Application Discontinuation
- 2010-01-13 JP JP2011546748A patent/JP5619027B2/ja not_active Expired - Fee Related
- 2010-01-13 CA CA2748896A patent/CA2748896C/en not_active Expired - Fee Related
- 2010-01-13 ES ES10701340T patent/ES2397558T3/es active Active
- 2010-01-13 DK DK10701340.1T patent/DK2389166T3/da active
- 2010-01-13 BR BRPI1007237-3A patent/BRPI1007237B1/pt not_active IP Right Cessation
- 2010-01-13 KR KR1020117016128A patent/KR20110105798A/ko not_active Ceased
- 2010-01-13 PL PL10701340T patent/PL2389166T3/pl unknown
- 2010-01-13 MX MX2011007381A patent/MX2011007381A/es active IP Right Grant
- 2010-01-13 SI SI201030129T patent/SI2389166T1/sl unknown
- 2010-01-13 RU RU2011134964/15A patent/RU2537224C2/ru not_active IP Right Cessation
- 2010-01-13 SG SG2011052305A patent/SG173058A1/en unknown
- 2010-01-13 HR HRP20130108AT patent/HRP20130108T1/hr unknown
- 2010-01-13 WO PCT/EP2010/050343 patent/WO2010084066A1/en not_active Ceased
- 2010-01-13 PT PT107013401T patent/PT2389166E/pt unknown
- 2010-01-13 PE PE2016000386A patent/PE20160746A1/es unknown
- 2010-01-19 US US12/689,296 patent/US20100190835A1/en not_active Abandoned
- 2010-01-21 AR ARP100100131A patent/AR075041A1/es not_active Application Discontinuation
- 2010-01-22 TW TW099101817A patent/TWI406861B/zh not_active IP Right Cessation
2011
- 2011-06-20 IL IL213671A patent/IL213671A/en unknown
- 2011-06-23 ZA ZA2011/04670A patent/ZA201104670B/en unknown
- 2011-07-22 CL CL2011001777A patent/CL2011001777A1/es unknown
2012
- 2012-11-12 US US13/674,310 patent/US20130072529A1/en not_active Abandoned
- 2012-12-03 CY CY20121101181T patent/CY1113641T1/el unknown

Also Published As

Publication number	Publication date
RU2011134964A (ru)	2013-02-27
JP5619027B2 (ja)	2014-11-05
AR075041A1 (es)	2011-03-02
US20130072529A1 (en)	2013-03-21
CA2748896A1 (en)	2010-07-29
US20100190835A1 (en)	2010-07-29
PE20160746A1 (es)	2016-08-01
SI2389166T1 (sl)	2013-02-28
ZA201104670B (en)	2012-03-28
DK2389166T3 (da)	2012-12-17
KR20110105798A (ko)	2011-09-27
RU2537224C2 (ru)	2014-12-27
PL2389166T3 (pl)	2013-04-30
ES2397558T3 (es)	2013-03-07
BRPI1007237B1 (pt)	2019-05-28
KR20140002812A (ko)	2014-01-08
AU2010206249A1 (en)	2011-06-30
CN102292074A (zh)	2011-12-21
TWI406861B (zh)	2013-09-01
PE20120421A1 (es)	2012-05-04
AU2010206249B2 (en)	2015-07-09
IL213671A (en)	2015-11-30
EP2389166B1 (en)	2012-11-21
CL2011001777A1 (es)	2012-02-24
CA2748896C (en)	2017-01-03
CN102292074B (zh)	2013-08-21
HRP20130108T1 (hr)	2013-03-31
SG173058A1 (en)	2011-08-29
IL213671A0 (en)	2011-07-31
JP2012515741A (ja)	2012-07-12
MX2011007381A (es)	2011-08-12
WO2010084066A1 (en)	2010-07-29
TW201035089A (en)	2010-10-01
EP2389166A1 (en)	2011-11-30
PT2389166E (pt)	2013-01-08
CY1113641T1 (el)	2016-06-22

Publication	Publication Date	Title
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
SMT201700095B (is)	2017-03-08	Composizioni farmaceutiche per inalazione
SMT201700008B (it)	2017-03-08	Composizione farmaceutica
BRPI1012539A2 (pt)	2016-03-29	composições farmacêuticas
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
EP2451274A4 (en)	2014-04-02	Pharmaceutical compositions
DK3246018T3 (da)	2022-01-17	Farmaceutisk sammensætning
BRPI0920521A2 (pt)	2018-01-16	combinação farmacêutica
BR112012012108A2 (pt)	2016-04-05	composição farmacêutica compreendendo propofol
LT3061445T (lt)	2023-09-25	Labai koncentruotos farmacinės kompozicijos
SMT201400069B (it)	2014-07-07	Formulazione farmaceutica
DK2391349T3 (da)	2014-11-03	Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
EE201300005A (et)	2013-08-15	Ravimkoostis
DK2285413T3 (da)	2012-08-27	Farmaceutisk sammensætning
IT1394400B1 (it)	2012-06-15	Composizioni farmaceutiche
EP2236149A4 (en)	2012-12-26	MEDICAL COMPOSITION
BRPI0921313A2 (pt)	2015-12-29	composição farmaucêutica
BR112012000831A2 (pt)	2019-09-24	compostos, composições farmacêuticas e métodos relacionados
BRPI0922653A2 (pt)	2016-01-05	preparação farmacêutica
BR112012003149A2 (pt)	2016-03-01	composição farmacêutica
BR112012001340A2 (pt)	2016-03-15	composições farmacêuticas
BRPI0912171A2 (pt)	2017-10-31	composição farmacêutica
BRPI1007237A2 (pt)	2016-02-16	composição farmacêutica compreendendo aleglitazar
BRPI0921301A2 (pt)	2015-12-29	composição farmacêutica

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-05-15	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-01-08	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-04-09	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-05-28	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2010, OBSERVADAS AS CONDICOES LEGAIS
2021-02-02	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 11A ANUIDADE.
2021-05-18	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2613 DE 02-02-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.